Director/PDMR Shareholding

Regulatory News Service

28 July 2017 11:00 BST


TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES
Disclosure under Article 19 of the EU Market Abuse Regulation

28 July 2017

AstraZeneca PLC (the Company) announces that, on 27 July 2017, it was notified by Nazneen Rahman, a Non-Executive Director of the Company, that, on 27 July 2017, Professor Rahman purchased 500 Ordinary Shares of $0.25 each in the Company (Shares) at an aggregate price of 4338.186 pence per Share.

The Company also announces that, on 27 July 2017, it was notified by Philip Broadley, a Non-Executive Director of the Company, that, on 27 July 2017, Mr Broadley purchased 2,300 Shares at a price of 4282 pence per Share.

The attached notifications, made in accordance with the requirements of the EU Market Abuse Regulation, give further detail.

1

 

Details of the person discharging managerial responsibilities / person closely associated

 

a)

 

Name

 

 

Nazneen Rahman

2

 

Reason for the notification

 

a)

 

Position/status

 

 

Non-Executive Director

b)

 

Initial notification /Amendment

 

 

Initial notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

a)

 

Name

 

 

AstraZeneca PLC

b)

 

LEI

 

 

PY6ZZQWO2IZFZC3IOL08

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

 

a)

 

Description of the financial instrument, type of instrument

 

Identification code

 

 

Ordinary Shares of US$0.25 each in AstraZeneca PLC

 

 

GB0009895292

 

b)

 

Nature of the transaction

 

 

Share purchase

c)

 

Price(s) and volume(s)

 

 

 

Price(s)

 

Volume(s)

4335.4837 pence

461

4370.1282 pence

39

 

 

d)

 

Aggregated information

 

 

- Aggregated volume

 

 

- Price

 

 

 

 

 

500

 

 

4338.1860 pence

 

e)

 

Date of the transaction

 

 

27 July 2017

f)

 

Place of the transaction

 

 

XLON

 

1

 

Details of the person discharging managerial responsibilities / person closely associated

 

a)

 

Name

 

 

Philip Broadley

2

 

Reason for the notification

 

a)

 

Position/status

 

 

Non-Executive Director

b)

 

Initial notification /Amendment

 

 

Initial notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

a)

 

Name

 

 

AstraZeneca PLC

b)

 

LEI

 

 

PY6ZZQWO2IZFZC3IOL08

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

 

a)

 

Description of the financial instrument, type of instrument

 

Identification code

 

 

Ordinary Shares of US$0.25 each in AstraZeneca PLC

 

 

GB0009895292

 

b)

 

Nature of the transaction

 

 

Share purchase

c)

 

Price(s) and volume(s)

 

 

 

Price(s)

 

Volume(s)

4282 pence

2,300

 

 

d)

 

Aggregated information

 

 

- Aggregated volume

 

 

- Price

 

 

Not applicable – single transaction

 

 

 

e)

 

Date of the transaction

 

 

27 July 2017

f)

 

Place of the transaction

 

 

XLON

About AstraZeneca

AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three main therapy areas - Oncology, Cardiovascular & Metabolic Diseases and Respiratory. The Company also is selectively active in the areas of autoimmunity, neuroscience and infection. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information, please visit www.astrazeneca.com and follow us on Twitter @AstraZeneca.


CONTACTS

Media Enquiries

 

 

 

 

Esra Erkal-Paler

UK/Global

+44 203 749 5638

Karen Birmingham

UK/Global

+44 203 749 5634

Rob Skelding

UK/Global

+44 203 749 5821

Matt Kent

UK/Global

+44 203 749 5906

Jacob Lund

Sweden

+46 8 553 260 20

Michele Meixell

US

+1 302 885 2677

 

 

 

Investor Enquiries

 

 

Thomas Kudsk Larsen

 

+44 203 749 5712

Craig Marks

Finance, Fixed Income, M&A

+44 7881 615 764

Henry Wheeler

Oncology

+44 203 749 5797

Mitchell Chan

Oncology

+1 240 477 3771

Lindsey Trickett

Cardiovascular & Metabolic Diseases

+1 240 543 7970

Nick Stone

Respiratory

+44 203 749 5716

Christer Gruvris

Autoimmunity, neuroscience & infection

+44 203 749 5711

US Toll-Free

 

+1 866 381 7277

 

Adrian Kemp

Company Secretary, AstraZeneca PLC

tags

  • Regulatory